Кенија - Енглески - Pharmacy and Poisons Board

vildagliptin - coated tablet - vildagliptin 50mg - vildagliptin

Кенија - Енглески - Pharmacy and Poisons Board

ajanta pharma limited b-4-5-6, midc industrial area paithan, - vildagliptin 100mg - tablet - vildagliptin 100mg - vildagliptin

Кенија - Енглески - Pharmacy and Poisons Board

ajanta pharma limited b-4-5-6, midc industrial area paithan, - vildagliptin 50mg - tablet - vildagliptin 50mg - vildagliptin

Зимбабве - Енглески - Medicines Control Authority

novartis south africa (pty) ltd - vildagliptin - tablet; oral - 50mg

Арменија - Енглески - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

denk pharma gmbh & co. kg - vildagliptin - tablets - 50mg

Израел - Енглески - Ministry of Health

novartis israel ltd - metformin hydrochloride; vildagliptin - film coated tablets - vildagliptin 50 mg; metformin hydrochloride 850 mg - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:- eucreas is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.- eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.- eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - vildagliptin - tablet - 50mg

Сингапур - Енглески - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - vildagliptin - tablet - 50mg - vildagliptin 50mg

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - vildagliptin 50mg;  ;   - tablet - 50 mg - active: vildagliptin 50mg     excipient: lactose magnesium stearate microcrystalline cellulose sodium starch glycolate - galvus is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus · as monotherapy · in dual combination with metformin, a sulphonylurea (su), or a thiazolidinedione (tzd) when diet, exercise and a single antidiabetic agent do not result in adequate glycaemic control. · in triple combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control · in combination with insulin (with or without metformin) when diet, exercise, and a stable dose of insulin do not result in adequate glycaemic control.

Кенија - Енглески - Pharmacy and Poisons Board

vildagliptin 50mg metformin hydrochloride 1000mg - coated tablet - vildagliptin 50mg metformin hydrochloride 1000mg - metformin and vildagliptin